Erasca Inc (ERAS)

Name: Erasca Inc (ERAS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Erasca Inc (ERAS)

Stock Card

$18.37

$-1.13 (-5.77%)

As on 28-Aug-2026 13:36EDT

Market cap

$6,166 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

16.5

Div. Yield

0 %

Erasca Inc (ERAS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 18.24 High: 19.59

52 Week Range

Low: 1.33 High: 24.28

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.6
Debt to Equity

0
Book Value

$--
EPS

$-1
Face value

--
Shares outstanding

349,762,035

5 Years Aggregate

CFO

$-327.15 Mln

EBITDA

$-227.64 Mln

Net Profit

$-697.10 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Erasca Inc (ERAS)	393.7	-2.7	47.3	1,062.3	91.4	-4.4	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Erasca Inc (ERAS)	48.2	17.7	-50.6	-72.3
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Erasca Inc (ERAS)	18.4	6,166.3	0.0	-287.2	--	-83.6	--	16.5
Arrowhead Pharmaceuticals (ARWR)	84.9	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Cytokinetics Inc (CYTK)	72.3	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.2	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	105.3	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Krystal Biotech (KRYS)	350.5	10,258.4	440.5	241.5	33.4	18.7	42.2	7.3
Madrigal Pharmaceuticals (MDGL)	534.5	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	603.9	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	348.4	10,496.2	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	142.6	9,985.8	282.0	82.9	-28.6	11.4	147	11.6

Shareholding Pattern

View Details

About Erasca Inc (ERAS)

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular... glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. Read more

Co-Founder, Chairman & CEO

Dr. Jonathan E. Lim M.D.
Co-Founder, Chairman & CEO

Dr. Jonathan E. Lim M.D.
Headquarters

San Diego, CA
Website

https://www.erasca.com

FAQs for Erasca Inc (ERAS)

What is the current share price of Erasca Inc (ERAS) Today?

The share price of Erasca Inc (ERAS) is $18.37 (NASDAQ) as of 28-Aug-2026 13:36 EDT. Erasca Inc (ERAS) has given a return of 91.38% in the last 3 years.

What is the current PB & PE ratio of Erasca Inc (ERAS)?

Since, TTM earnings of Erasca Inc (ERAS) is negative, P/E ratio is not available.
The P/B ratio of Erasca Inc (ERAS) is 16.50 times as on 21-Aug-2026, a 208 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.